These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34248473)

  • 21. Cyclin-dependent kinase 4/6 inhibitors: what have we learnt across studies, therapy situations and substances.
    Banys-Paluchowski M; Krawczyk N; Paluchowski P
    Curr Opin Obstet Gynecol; 2019 Feb; 31(1):56-66. PubMed ID: 30520756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors.
    Ettl J
    Breast Care (Basel); 2019 Apr; 14(2):86-92. PubMed ID: 31798379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER2- Breast Cancer: A Systematic Review and Meta-Analysis.
    Hong K; Yao L; Sheng X; Ye D; Guo Y
    Oncol Res Treat; 2021; 44(10):557-567. PubMed ID: 34515204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial.
    Goel S; Pernas S; Tan-Wasielewski Z; Barry WT; Bardia A; Rees R; Andrews C; Tahara RK; Trippa L; Mayer EL; Winer EP; Spring LM; Tolaney SM
    Clin Breast Cancer; 2019 Dec; 19(6):399-404. PubMed ID: 31235441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
    Mistry R; Suri G; Young K; Hettle R; May JR; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya D; Bhattacharyya S; Mishra D; Dalal AA
    Curr Med Res Opin; 2018 Dec; 34(12):2143-2150. PubMed ID: 30032697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer.
    García-Trevijano Cabetas M; Lucena Martínez P; Jiménez Nácher I; Díaz Almirón M; Zamora Auñón P; Herrero Ambrosio A
    Int J Clin Pharm; 2021 Aug; 43(4):893-899. PubMed ID: 33170404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatotoxicity After CDK 4/6 Inhibitor Initiation in the Treatment of Hormone-Positive Metastatic Breast Cancer.
    Wani K; Patel K; Dabak V
    Cureus; 2023 Jun; 15(6):e40871. PubMed ID: 37363122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
    Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
    J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data.
    Abdel-Razeq H; Sharaf B; AlMasri R; Abdel-Razeq R; Tamimi F; Khader O; Salama O; Abunasser M; Edaily S; Abdulelah H
    Cancer Manag Res; 2022; 14():1033-1041. PubMed ID: 35300061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
    Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Petrakova K; Blackwell KL; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Mondal S; Su F; Miller M; Elmeliegy M; Germa C; O'Shaughnessy J
    Ann Oncol; 2018 Jul; 29(7):1541-1547. PubMed ID: 29718092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New Drugs, Old Toxicities: Pneumonitis Related to Palbociclib - A Case Report.
    Felip E; Llobera L; Perez-Mañá C; Quintela D; Guasch I; Margelí M; Teruel I; Cirauqui B; Centeno C; Romeo M; Ballana E; Quiroga V
    Breast Care (Basel); 2020 Oct; 15(5):548-552. PubMed ID: 33224001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis.
    Becherini C; Visani L; Caini S; Bhattacharya IS; Kirby AM; Nader Marta G; Morgan G; Salvestrini V; Coles CE; Cortes J; Curigliano G; de Azambuja E; Harbeck N; Isacke CM; Kaidar-Person O; Marangoni E; Offersen B; Rugo HS; Morandi A; Lambertini M; Poortmans P; Livi L; Meattini I
    Cancer Treat Rev; 2023 Sep; 119():102586. PubMed ID: 37336117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
    Kalinsky K; Accordino MK; Chiuzan C; Mundi PS; Sakach E; Sathe C; Ahn H; Trivedi MS; Novik Y; Tiersten A; Raptis G; Baer LN; Oh SY; Zelnak AB; Wisinski KB; Andreopoulou E; Gradishar WJ; Stringer-Reasor E; Reid SA; O'Dea A; O'Regan R; Crew KD; Hershman DL
    J Clin Oncol; 2023 Aug; 41(24):4004-4013. PubMed ID: 37207300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
    Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Blackwell KL; André F; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Petrakova K; Hart LL; Villanueva C; Chan A; Jakobsen E; Nusch A; Burdaeva O; Grischke EM; Alba E; Wist E; Marschner N; Favret AM; Yardley D; Bachelot T; Tseng LM; Blau S; Xuan F; Souami F; Miller M; Germa C; Hirawat S; O'Shaughnessy J
    N Engl J Med; 2016 Nov; 375(18):1738-1748. PubMed ID: 27717303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer.
    Thill M; Schmidt M
    Ther Adv Med Oncol; 2018; 10():1758835918793326. PubMed ID: 30202447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck.
    Seront E; Schmitz S; Papier M; van Maanen A; Henry S; Lonchay C; Rottey S; van Caloen G; Machiels JP
    Front Oncol; 2019; 9():155. PubMed ID: 30941307
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [No Abstract]   [Full Text] [Related]  

  • 38. Integration of Postoperative Radiation Therapy with Cyclin-Dependent Kinase (CDK) Inhibitors.
    Yoshimoto FH; de Sousa CFPM; Marta GN; Hanna SA
    Curr Oncol Rep; 2023 Oct; 25(10):1153-1159. PubMed ID: 37624551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis.
    Onesti CE; Jerusalem G
    Expert Rev Anticancer Ther; 2021 Mar; 21(3):283-298. PubMed ID: 33233970
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
    Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
    Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.